What Resolution Therapeutics does

Resolution Therapeutics Limited is a clinical-stage biopharmaceutical company developing Regenerative Macrophage Therapy (RMT) to treat inflammatory and fibrotic diseases, with an initial focus on end-stage liver disease. The company was founded in 2020 as a spinout from the University of Edinburgh's Centre for Regenerative Medicine, based on more than a decade of founders' research into the role of macrophages in organ repair. Its core technology is an ex vivo autologous cell therapy platform in which monocytes are collected from a patient's blood via leukapheresis, differentiated into pro-regenerative macrophages, engineered with therapeutic genes — including IL-10 (anti-inflammatory) and MMP9 (anti-fibrotic) — and re-infused intravenously. The lead product RTX001 is being evaluated in the open-label EMERALD Phase I/II study across 15 hepatology centers in the UK and Spain, enrolling up to 25 patients with decompensated cirrhosis; first patient was dosed in September 2025, with interim data expected in H2 2026.

The company's pipeline also includes an in vivo RMT program announced in June 2026, which uses proprietary mRNA payloads delivered via lipid nanoparticles to programme macrophages inside the body without ex vivo manufacturing, alongside preclinical-stage programs in graft-versus-host disease and lung fibrosis. Manufacturing is supported by academic and consortium partnerships: the Scottish National Blood Transfusion Service supplies GMP-grade macrophages, the University of Edinburgh provides licensed IP, CCRM/OmniaBio and panCELLa enable allogeneic iPSC-derived programs, and an Innovate UK-funded consortium with Cellular Origins and CGT Catapult is automating cell therapy manufacturing at Stevenage. The OPAL natural history study was set up in parallel to inform control-arm interpretation.

Resolution Therapeutics is privately held, registered in England and headquartered in London (245 Hammersmith Road) with R&D operations at the University of Edinburgh's Centre for Regenerative Medicine. It has raised approximately £100.1 million in disclosed funding — a £26.6m Series A (December 2020), a £10m Series A extension (April 2022) and a £63.5m Series B (October 2024) — entirely from Syncona Ltd, the London-listed life sciences investment firm. The commercial model is conventional biopharma product sales post-regulatory approval rather than current revenue generation; pricing is undisclosed. The company is led by CEO Amir Hefni (previously Global Head of Cell and Gene Therapy at Novartis), with Chairman Paul Sekhri (CEO of vTv Therapeutics; ex-eGenesis, Lycera, Novartis SVP BD&L) and a board that includes Syncona partners.

Name

Resolution Therapeutics

Legal name

Resolution Therapeutics Limited

Website

https://resolution-tx.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

51–100 employees

Short description

Resolution Therapeutics is a clinical-stage biopharmaceutical company developing engineered Regenerative Macrophage Therapy (RMT), initially autologous RTX001 with IL-10/MMP9 for end-stage liver disease, targeting decompensated cirrhosis patients in the UK, Spain, the US and Europe.

Ownership category

akta.pro rank

Product category

Cell Therapy Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Dendritic Cell & Other APC-based Therapies (HLAAABAF)

akta.pro secondary industry

Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics) (HLAAAGAL)

Keywords

• Macrophage cell therapy
• Regenerative macrophage therapy
• Engineered cell therapy
• Liver disease therapeutics
• Cell therapy manufacturing

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Biopharmaceutical / Cell Therapy Revenue: Resolution Therapeutics is a clinical-stage biopharmaceutical company with no current revenue. The company is developing macrophage cell therapy products (RTX001 and in vivo RMT) targeting inflammatory and fibrotic diseases, with end-stage liver disease as the primary indication. Revenue is expected to be generated through product sales following regulatory approval, with potential for both autologous (personalized) and allogeneic (off-the-shelf) product offerings.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Resolution Therapeutics is a clinical-stage biopharmaceutical company developing Regenerative Macrophage Therapy (RMT) for inflammatory and fibrotic diseases. Its lead asset RTX001 is an engineered autologous macrophage cell therapy enhanced with IL-10 and MMP9 therapeutic genes, currently in a Phase I/II EMERALD clinical trial for end-stage liver disease (decompensated cirrhosis). The company also operates a proprietary platform for macrophage differentiation, engineering, and cryopreserved manufacturing, and is developing a next-generation in vivo RMT program using mRNA delivered via lipid nanoparticles.

Product overview

Resolution Therapeutics is a clinical-stage biopharmaceutical company pioneering Regenerative Macrophage Therapy (RMT) in inflammatory and fibrotic diseases. The company's product portfolio is anchored by its proprietary RMT platform, which underlies two therapeutic approaches: an ex vivo engineered autologous cell therapy (RTX001) and a next-generation in vivo program using mRNA delivered via lipid nanoparticles. Lead product RTX001 is an engineered autologous macrophage therapy enhanced with IL-10 and MMP9, currently in a Phase I/II EMERALD trial for end-stage liver disease. The company also operates the OPAL natural history study and is developing an in vivo RMT program. Prior clinical validation comes from the MATCH Phase 2 trial of non-engineered macrophages, which demonstrated 70% transplant-free survival at four years.

Differentiator

Problem solved

Functional benefit

Products and services

• RTX001 RTX001 is Resolution Therapeutics' lead engineered autologous regenerative macrophage cell therapy, designed to deliver increased anti-fibrotic and anti-inflammatory effects in patients with end-stage liver disease. It is engineered ex vivo with a unique combination of therapeutic genes including IL-10 (anti-inflammatory) and MMP9 (anti-fibrotic/metalloprotease) to enhance the inherent regenerative properties of macrophages for superior efficacy and durability, representing a first-in-class potential treatment for decompensated liver cirrhosis.
• In Vivo Regenerative Macrophage Therapy (RMT) Program Next-generation in vivo Regenerative Macrophage Therapy program that uses proprietary mRNA delivered via lipid nanoparticles (LNPs) to reprogram immune cells directly inside the patient, eliminating the need for cell collection or ex vivo manufacturing. The program complements Resolution's autologous RTX001 therapy and is intended to extend RMT to broader patient populations across inflammatory and fibrotic diseases.

Quantifiable outcome

• 70% transplant-free survival at 4 years vs 40% in control group (MATCH Phase 2, non-engineered macrophages)
• +4 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered minor and core.

• Cellular OriginsminorStrategic or Co-development Partner · 14 July 2025Cellular Origins, Cell and Gene Therapy Catapult, and Resolution Therapeutics formed a consortium that won a £1m Innovate UK Smart Grant to develop a fully automated, scalable cell and gene therapy manufacturing platform. The 20-month project installs Cellular Origins' Constellation robotic system at CGT Catapult's Stevenage site. Resolution participates as a consortium partner providing therapeutic macrophage manufacturing use case. Additional support from ScaleReady (bioreactor) and Autolomous (electronic batch record platforms).
• CCRM / OmniaBio Inc.minorStrategic or Co-development Partner · 7 November 2022Resolution Therapeutics signed a collaboration agreement with CCRM and its subsidiary OmniaBio Inc. to develop and scale up a manufacturing platform for Resolution's off-the-shelf iPSC-derived macrophage cell therapies. OmniaBio will leverage its technical expertise in iPSC differentiation, process development and GMP manufacturing to build a scalable manufacturing platform for Resolution's allogeneic macrophage programs.
• panCELLa Inc.minorStrategic or Co-development Partner · 5 April 2022Resolution Therapeutics entered a Research Evaluation and Option Agreement with panCELLa Inc. to develop iPSC-derived macrophage cell therapy for inflammatory organ disease. panCELLa provides its hypo-immunogenic engineered iPSC technology (FailSafe safety switch and iACT StealthCells for immune evasion) to support Resolution's allogeneic macrophage program. Resolution holds an option to obtain commercial rights to use the panCELLa technology in macrophage biology.
• University of Edinburgh / Edinburgh InnovationscoreStrategic or Co-development PartnerResolution Therapeutics is a spinout from Professor Stuart Forbes' laboratory at the University of Edinburgh's Centre for Regenerative Medicine. The company was founded following a two-year research collaboration (2018-2020) with the University of Edinburgh. Resolution holds exclusive licensing rights to the macrophage cell therapy technology and data developed at the university. Susan Bodie (Head of Business Development, Edinburgh Innovations) serves as Board Observer.
• Scottish National Blood Transfusion Service (SNBTS)minorStrategic or Co-development PartnerResolution partnered with SNBTS to optimise the macrophage manufacturing process and produce GMP-grade engineered macrophages for clinical use. SNBTS provided clinical macrophage material for the academic MATCH trial and continues as a manufacturing partner. Professor John Campbell, Director of Tissues, Cells & Advanced Therapeutics at SNBTS, is a co-founder of Resolution.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Lygenesis: Clinical-stage cell therapy company developing allogeneic liver cell therapy for end-stage liver disease. Direct competitor in liver cell therapy with overlapping indication (decompensated cirrhosis) and similar autologous/allogeneic strategy overlap.
• HepaTx (formerly Promethera Biosciences): Cell therapy company developing liver-derived cell therapies for liver disease and urea cycle disorders. Direct peer in liver cell therapy targeting similar patient populations of advanced liver disease.
• Capricor Therapeutics: Clinical-stage biotechnology company developing cell therapy (CAP-1002, cardiosphere-derived cells) for inflammatory and fibrotic indications. Comparable in therapeutic modality (allogeneic cell therapy), inflammatory/fibrotic disease focus, and clinical-stage status.
• Mesoblast: Commercial-stage cell therapy company developing mesenchymal stem cell therapies for inflammatory diseases (e.g., remestemcel-L for GvHD). Highly comparable in cell therapy modality, inflammatory disease focus, and pipeline overlap in GvHD.

Broad incumbents

• Madrigal Pharmaceuticals: Commercial-stage biopharmaceutical company with approved resmetirom (Rezdiffra) for MASH/NASH. Comparable as a liver-focused biopharmaceutical competitor addressing the same underlying patient population as Resolution's end-stage liver program.
• Vertex Pharmaceuticals: Large biopharmaceutical company with approved Casgevy (gene-edited cell therapy) and active cell/gene therapy pipeline including in vivo programs. Comparable as a large, well-capitalized cell/gene therapy player pursuing novel cell-based modalities.
• bluebird bio: Cell and gene therapy company with commercialized autologous gene-modified cell therapies (e.g., Lyfgenia, Zynteglo). Comparable as an established cell therapy player with operational experience in autologous manufacturing and regulatory navigation.

Emerging players

• Shoreline Biosciences: Clinical-stage cell therapy company developing iPSC-derived natural killer (NK) cell and macrophage therapies for cancer and inflammatory diseases. Highly comparable in myeloid cell therapy platform focus and iPSC-derived macrophage strategy overlap.
• Verve Therapeutics: Clinical-stage biotechnology company pioneering in vivo gene editing using LNP-delivered base editing technologies. Comparable to Resolution's in vivo RMT program in applying LNP-delivered nucleic acid payloads to program cells inside the body.
• Pluristem Therapeutics: Cell therapy company developing placenta-derived allogeneic cell therapies for inflammatory and ischemic conditions. Comparable as a cell therapy company focused on inflammatory disease indications and manufacturing scale-up.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/ResolutionTx
• LinkedInlinkedin.com/company/resolution-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Resolution Therapeutics